동물 바이오테크놀러지 시장 : 제품 유형, 기술, 동물 유형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Animal Biotechnology Market is projected to grow by USD 60.56 billion at a CAGR of 8.68% by 2032.

Animal Biotechnology Executive Summary

Animal biotechnology is moving from a specialized research discipline into a core enabler of food security, animal health, sustainable livestock production, aquaculture productivity, and biomedical research. The field includes animal genomics, molecular diagnostics, reproductive biotechnology, gene editing, vaccines, biologics, microbiome solutions, transgenic and cloned animal models, and precision breeding tools used across livestock, companion animals, laboratory animals, and aquatic species.

Demand is supported by structural pressures documented by global agencies, including rising protein consumption, the need to control zoonotic diseases, antimicrobial resistance concerns, and climate-related stress on animal production systems. FAO, WHO, WOAH, and OECD evidence consistently shows that animal disease outbreaks can disrupt trade, food supply, farm income, and public health systems, making preventive animal health technologies, genomic selection, and rapid diagnostics increasingly strategic for producers, governments, veterinarians, and life science stakeholders.

Transformative Shifts in Animal Biotechnology

The animal biotechnology landscape is being reshaped by the convergence of genomics, synthetic biology, automation, and data-led animal health management. Genomic selection is now widely used in dairy, poultry, swine, and aquaculture breeding programs to improve productivity, disease resistance, fertility, feed efficiency, and resilience, while CRISPR-based gene editing is accelerating research into traits that can reduce disease susceptibility, improve animal welfare, and support more sustainable production systems.

Another transformative shift is the movement from reactive treatment to preventive and predictive animal health. Rapid PCR, sequencing-based diagnostics, recombinant vaccines, monoclonal antibodies, and herd-level surveillance systems are enabling earlier intervention. At the same time, regulatory scrutiny, consumer acceptance, animal welfare expectations, antimicrobial stewardship, and traceability requirements are shaping commercialization pathways for genetically engineered animals and biotechnology-derived products.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the impact of animal biotechnology by improving the speed, accuracy, and scalability of discovery and field deployment. AI-driven genomic analysis helps identify markers linked to economically important traits, while machine learning models can support breeding decisions by integrating phenotype, genotype, feed, environment, and health records. In veterinary medicine, AI is increasingly applied to image interpretation, pathogen detection, outbreak modeling, pharmacovigilance, and precision dosing research.

The cumulative effect is a shorter innovation cycle across animal biotechnology. AI-enabled laboratories can prioritize vaccine antigens, optimize biologics development, and interpret high-throughput sequencing data more efficiently. On farms and in aquaculture systems, AI tools connected to sensors, cameras, wearables, electronic identification, and diagnostics support early disease detection and welfare monitoring, helping reduce losses and improve productivity when implemented with validated datasets, strong cybersecurity, interoperable data systems, and transparent governance.

Key Regional Insights

Asia-Pacific is a high-priority region for animal biotechnology, driven by large animal protein demand, aquaculture scale, poultry and swine intensification, and government-backed biotechnology programs in China, India, Japan, South Korea, and Australia. The region is increasingly focused on vaccines, molecular diagnostics, swine biosecurity, shrimp and fish health, genomic selection, and reproductive technologies to improve productivity and reduce disease-related losses across diverse production systems.

North America remains a leading region for animal biotechnology due to advanced veterinary biopharma capabilities, strong university research, established livestock genetics infrastructure, and regulatory experience with biotechnology-derived animal products. The United States and Canada benefit from large commercial livestock industries, companion animal health spending, genomic evaluation systems, and mature disease surveillance networks that support precision breeding, veterinary biologics, and One Health preparedness.

Latin America, led by Brazil and Mexico, is adopting animal genetics, reproductive technologies, vaccines, and diagnostics to improve export competitiveness in beef, poultry, dairy, and swine. Europe is shaped by strong animal welfare rules, rigorous biosafety oversight, and public investment in genomics, vaccines, alternatives to antimicrobials, and One Health surveillance, with the European Union's regulatory framework influencing adoption timelines. The Middle East is investing in food security, veterinary diagnostics, biosecure production, camel health, and small ruminant health, while Africa's opportunity is linked to disease control, heat-tolerant breeds, vaccine access, molecular diagnostics, and productivity improvement for smallholder and commercial livestock systems.

Key Group Insights

ASEAN is gaining relevance in animal biotechnology through poultry, aquaculture, and swine production, especially as governments strengthen disease surveillance and biosecurity after major transboundary disease events. The region's needs are closely tied to rapid diagnostics, vaccines, breeding improvement, aquaculture health, and practical technologies that can be deployed across both intensive and smallholder systems.

GCC markets are focused on food security, import substitution, high-value animal health, and biotechnology applications suited to arid environments and regional livestock systems, including camel, dairy, poultry, and small ruminant production. The European Union provides one of the most influential policy environments for animal biotechnology through harmonized standards for veterinary medicines, food safety, animal welfare, environmental risk assessment, and antimicrobial reduction, creating a demanding but high-value environment for compliant diagnostics, vaccines, and breeding technologies.

BRICS countries are critical to production scale and technology adoption, with China, India, and Brazil playing major roles in livestock, aquaculture, vaccine manufacturing, genomics, and disease control. G7 countries are central to animal biotechnology innovation because they combine advanced research infrastructure, mature veterinary pharmaceutical ecosystems, strong intellectual property systems, and regulatory science. NATO members add a biosecurity dimension, with zoonotic disease preparedness, supply chain resilience, laboratory capability, and surveillance systems becoming increasingly important for national security and food system resilience planning.

Key Country Insights

The United States leads in animal biotechnology commercialization through advanced animal genomics, veterinary biologics, companion animal therapeutics, molecular diagnostics, and academic-industry collaboration. Canada is strong in livestock genetics, vaccine research, dairy and beef innovation, and animal health surveillance, while Mexico is expanding veterinary diagnostics and production technologies linked to poultry, beef, dairy, and swine supply chains. Brazil is a major platform because of its global role in beef and poultry exports, supported by breeding, reproductive technologies, vaccines, and biosecurity investment.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong capabilities in veterinary research, livestock genetics, animal welfare science, diagnostics, and vaccine development, although adoption of gene-edited animals depends on evolving regulatory pathways and consumer acceptance. Russia remains relevant in livestock disease control, domestic vaccine capacity, veterinary surveillance, and agricultural biotechnology priorities.

China is scaling animal biotechnology through genomics, gene editing research, vaccines, swine biosecurity, disease surveillance, and aquaculture innovation. India's opportunity is tied to dairy productivity, animal vaccines, reproductive technologies, molecular diagnostics, and disease control for a large livestock base. Japan and South Korea emphasize precision animal health, advanced diagnostics, biotechnology research, biosecurity, and high-value livestock systems, while Australia is important for livestock genetics, biosecurity, reproductive biotechnology, disease preparedness, and export-oriented animal health standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated, field-ready animal biotechnology solutions that address measurable pain points such as disease losses, reproductive efficiency, feed conversion, animal welfare, heat stress resilience, aquaculture mortality, and antimicrobial reduction. Organizations can improve adoption by pairing biotechnology products with diagnostics, data platforms, training, veterinary support, and outcome-based evidence for producers, veterinarians, regulators, and public health stakeholders.

Strategic investment should focus on genomic selection, rapid diagnostics, next-generation vaccines, biologics, microbiome products, reproductive biotechnology, aquaculture health, and AI-enabled decision support. Leaders should also build regulatory affairs capabilities early, establish transparent animal welfare and biosafety documentation, protect genomic and farm data, validate claims through field trials, and form partnerships with universities, reference laboratories, producer groups, and public health agencies to strengthen credibility and market access.

Research Methodology

Research methodology is based on secondary research that synthesizes publicly available and institutionally recognized sources, including FAO, WOAH, WHO, OECD, USDA, FDA, EMA, EFSA, national agriculture departments, peer-reviewed journals, patent databases, regulatory publications, and veterinary industry sources. The analysis focuses on verifiable trends in animal genomics, veterinary biologics, molecular diagnostics, reproductive biotechnology, gene editing, aquaculture biotechnology, microbiome science, and AI-enabled animal health.

The research approach evaluates technology maturity, regulatory direction, regional production systems, disease burden, commercialization readiness, animal welfare considerations, biosecurity priorities, and adoption drivers. Insights are triangulated across scientific evidence, public policy, regulatory activity, market deployment patterns, and industry use cases to support an authoritative view of the animal biotechnology landscape without relying on unverified claims, market sizing, market share, or forecasting.

Conclusion

Animal biotechnology is becoming a strategic pillar for resilient animal agriculture, veterinary medicine, aquaculture, biomedical research, and sustainable protein production. As disease pressure, climate risk, antimicrobial stewardship, zoonotic threats, and food security concerns intensify, biotechnology-enabled breeding, diagnostics, vaccines, biologics, and AI-supported analytics will play a larger role in improving animal productivity, health outcomes, and welfare.

The next phase of advancement will be defined by responsible innovation. Organizations that combine scientific validation, regulatory readiness, ethical governance, biosafety, transparent data practices, and clear economic value for producers and veterinarians will be best positioned to lead in the animal biotechnology landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Animal Biotechnology Market, by Product Type

• 7.1. Recombinant Proteins
  • 7.1.1. Antibodies
  • 7.1.2. Enzymes
    • 7.1.2.1. Lipases
    • 7.1.2.2. Phytases
    • 7.1.2.3. Proteases
  • 7.1.3. Growth Hormones
• 7.2. Vaccines
  • 7.2.1. DNA Vaccines
  • 7.2.2. Inactivated Vaccines
  • 7.2.3. Live Attenuated Vaccines
  • 7.2.4. Subunit Vaccines

8. Animal Biotechnology Market, by Technology

• 8.1. Cell Culture
  • 8.1.1. Avian Cell Culture
  • 8.1.2. Insect Cell Culture
  • 8.1.3. Mammalian Cell Culture
• 8.2. Genetic Engineering
  • 8.2.1. Gene Editing
  • 8.2.2. Gene Synthesis
  • 8.2.3. Transgenic Technology
• 8.3. PCR And DNA Sequencing
  • 8.3.1. Next-Generation Sequencing
  • 8.3.2. PCR Kits
  • 8.3.3. Sanger Sequencing

9. Animal Biotechnology Market, by Animal Type

• 9.1. Livestock
  • 9.1.1. Cattle
  • 9.1.2. Poultry
  • 9.1.3. Swine
• 9.2. Companion Animals
  • 9.2.1. Dogs
  • 9.2.2. Cats

10. Animal Biotechnology Market, by Application

• 10.1. Diagnostics
  • 10.1.1. ELISA Kits
  • 10.1.2. Lateral Flow Assays
  • 10.1.3. PCR-Based Tests
• 10.2. Drug Discovery
  • 10.2.1. Lead Optimization
  • 10.2.2. Preclinical Testing
  • 10.2.3. Target Identification
• 10.3. Feed Additives
  • 10.3.1. Carbohydrases
  • 10.3.2. Phytases
  • 10.3.3. Proteases

11. Animal Biotechnology Market, by End-User

• 11.1. Animal Farms
• 11.2. Contract Research Organizations
• 11.3. Pharmaceutical Companies
• 11.4. Research Laboratories

12. Animal Biotechnology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Animal Biotechnology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Animal Biotechnology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abaxis, Inc.
• 16.2. Bio-Rad Laboratories, Inc.
• 16.3. BioChek B.V.
• 16.4. Biogenesis Bago S.A.
• 16.5. Bioniche Life Sciences Inc.
• 16.6. Boehringer Ingelheim International GmbH
• 16.7. Ceva Sante Animale
• 16.8. Covetrus, Inc.
• 16.9. Creative Biolabs, Inc.
• 16.10. Dechra Pharmaceuticals PLC
• 16.11. Elanco Animal Health Incorporated
• 16.12. Genus plc
• 16.13. Henry Schein Animal Health
• 16.14. Heska Corporation
• 16.15. Hester Biosciences Limited
• 16.16. IDEXX Laboratories, Inc.
• 16.17. IDvet SAS
• 16.18. ImmuCell Corporation
• 16.19. Indian Immunologicals Limited
• 16.20. INDICAL Bioscience GmbH
• 16.21. Intas Pharmaceuticals Limited
• 16.22. Merck & Co., Inc.
• 16.23. Neogen Corporation
• 16.24. Neovet Diagnostics Pvt. Ltd.
• 16.25. Pharmgate Animal Health LLC
• 16.26. Phibro Animal Health Corporation
• 16.27. Randox Laboratories Ltd.
• 16.28. Recombinetics, Inc.
• 16.29. Santa Cruz Biotechnology, Inc.
• 16.30. Sequent Scientific Limited
• 16.31. Thermo Fisher Scientific Inc.
• 16.32. Trans Ova Genetics, L.C.
• 16.33. Vetoquinol S.A.
• 16.34. Virbac S.A.
• 16.35. Zoetis Inc.